Evaluation of the prevalence of adverse reactions to antimycobacterial drugs in pulmonary tuberculosis

Abstract

The development of adverse reactions (AR) against the background of anti-tuberculosis therapy reduces the effectiveness of the latter and causes additional damage to the health and life of the patient. In the structure of AR, one of the first places is occupied by drug-induced liver damage, the frequency of which ranges from 7 to 74%. The main component of TB treatment at the present stage is chemotherapy - long-term simultaneous administration of several anti-tuberculosis drugs (ATDs), most of which are potentially hepatotoxic. When using chemotherapy regimens (CT) that include only first-line drugs, the frequency of unwanted ADRs ranges from 8 to 61%; these figures reach 92%.